** Exane BNP Paribas restarts its coverage on Sonova SOON.S with "underperform", citing concerns over the Swiss hearing aids maker's full-year guidance
** Among main headwinds, the brokerage notes weaker underlying end markets, high competition and market share erosion
** It prefers Sonova's Danish rival "outperform"-rated Demant DEMANT.CO, which it sees as benefiting from the upcoming launch of its next-generation product
** Despite the 27% share price fall so far this year, the broker says it sees room for additional downside
** Out of 17 analysts that cover Sonova, four rate the stock "strong buy" or "buy," eight rate it "hold" and five rate "strong sell" or "sell" - LSEG data
(Reporting by Amir Orusov)
((Amir.orusov@thomsonreuters.com))